ASRS 2020: Impact of baseline OCT on response to risuteganib for treatment of intermediate AMD

Justis P. Ehlers, MD, speaks on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)."


Justis P. Ehlers, MD, of the Cole Eye Institute at the Cleveland Clinic, speaks with Ophthalmology Times®' David Hutton on the key takeaways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)" during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

See more ASRS meeting coverage here

Related Videos
DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden
Phase 4 Paladin finds fluocinolone to be safe, effective in patients with diabetic macular edema
Foundation Fighting Blindness: Building a toolbox of therapies for dry AMD, inherited retinal diseases
Faricimab for DME: Personalized treatment interval dosing maintains visual acuity, reduces treatment burden
Diabetic retinopathy eye drop: Phase 1B clinical results show promise
Quicker time to surgery affects VA outcomes in macula-on rhegmatogenous retinal detachments
Giant retinal tear-related detachments: Pediatric eyes repair better after vitrectomy with scleral buckling; adults only need vitrectomy
KALAHARI study: Phase 2 early results indicate alternative treatment pathway for patients with DME is effective, durable
Elevated albumin to creatinine ratio associated with central subfield thickness fluctuations in patients with DME
RGX-314 demonstrates DRSS improvements in patients with DME, NPDR
Related Content
© 2023 MJH Life Sciences

All rights reserved.